Summary

The goal of the current study is to review the published articles for pharmacoeconomic analyses of the highly active antiretroviral therapy (HAART) in patients with HIV/AIDS.

Systematic literature databases search was performed in Scopus, PubMed, Google Scholar  with key words HAART + pharmacoeconomics, HAART +cost of therapy. On total 77 studies were selected and analyzed.

Pharmaceoconomic evaluations are necessary and important, because they are part of the therapeutic, and managerial decision rules. An important part of such evaluations is the budget impact analysis of the new therapies.

Studies show that the burden of HIV infection is heavy for the society and individuals, especially in the developing countries. New therapies are developed with the aim to decrease the adverse therapeutic effects and toxicity of the new products part of the HAART. The future challenges remain the decrease in the cost of HIV medicines with the aim to ensure better access to therapy.